669066-89-1

Basic information

• Product Name: 3-AMINO-5-BROMOPYRIDINE-2-CARBOXAMIDE
• Synonyms: 3-AMINO-5-BROMOPYRIDINE-2-CARBOXAMIDE;3-Amino-5-bromopyridine-3-carboxamide
• CAS NO: 669066-89-1
• Molecular Formula: C₆H₆BrN₃O
• Molecular Weight: 216.04
• EINECS: 200-589-5
• Mol File: 669066-89-1.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 358.8 °C at 760 mmHg
• Flash Point: 170.8 °C
• Appearance: /
• Density: 1.802 g/cm³
• Vapor Pressure: 2.48E-05mmHg at 25°C
• Refractive Index: 1.678
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 14.56±0.50(Predicted)
• CAS DataBase Reference: 3-AMINO-5-BROMOPYRIDINE-2-CARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-5-BROMOPYRIDINE-2-CARBOXAMIDE(669066-89-1)
• EPA Substance Registry System: 3-AMINO-5-BROMOPYRIDINE-2-CARBOXAMIDE(669066-89-1)

Safety Data

• Hazard Codes: T
• Statements: 25-36-43
• Safety Statements: 26-36/37-45
• RIDADR: UN 2811 6.1 / PGIII
• HazardClass: IRRITANT
• Hazardous Substances Data: 669066-89-1(Hazardous Substances Data)

Usage

General Description

"3-Amino-5-bromopyridine-2-carboxamide" is a synthetic organic compound commonly used in pharmaceutical research and medicinal chemistry. 3-AMINO-5-BROMOPYRIDINE-2-CARBOXAMIDE pertains to brominated derivatives of pyridine, which are widely acknowledged for their biological activities. The molecule consists of a pyridine ring which contains a carboxamide group at the 2nd position, an amino group at the 3rd position, and a bromo group at the 5th position. Its chemical properties such as molecular weight, density, boiling point, melting point, etc., may vary depending on its purity and specific preparation methods. However, like other chemical compounds, it requires careful handling primarily to avoid skin/eye contact or inhalation.

InChI:InChI=1/C6H6BrN3O/c7-3-1-4(8)5(6(9)11)10-2-3/h1-2H,8H2,(H2,9,11)

Upstream product

• 412035-35-9 5-bromo-3-nitro-pyridine-2-carboxylic acid amide 
• 573675-25-9 5-bromo-3-nitropyridine-2-carbonitrile 
• 15862-37-0 2,5-dibromo-3-nitro-pyridine 
• 15862-34-7 5-bromo-3-nitro-2-pyridone 
• 870997-85-6 3-amino-5-bromo-pyridine-2-carboxylic acid 
• 1334405-60-5 ethyl 3-amino-5-bromopyridine-2-carboxylate 

Downstream Products

• 669066-90-4 5-bromo-3-fluoro-pyridine-2-carboxylic acid amide 
• 669066-91-5 5-bromo-3-fluoro-pyridine-2-carboxylic acid 
• 669066-93-7 5-bromo-3-fluoropyridine-2-carboxaldehyde 
• 943975-48-2 C₁₉H₂₂ClFN₂O₃S 
• 943975-64-2 C₁₅H₁₄ClFN₂O₂ 
• 943975-49-3 C₁₉H₂₁Cl₂FN₂O₃S 
• 761400-02-6 C₁₅H₁₃Cl₂FN₂O₂ 
• 943975-50-6 C₂₀H₂₄ClFN₂O₃S 
• 943975-65-3 C₁₆H₁₆ClFN₂O₂ 
• 943975-51-7 C₂₀H₂₃Cl₂FN₂O₃S 
• 943975-66-4 C₁₆H₁₅Cl₂FN₂O₂ 
• 943975-52-8 C₁₉H₂₁Cl₂FN₆OS 
• 943975-67-5 C₁₅H₁₃Cl₂FN₆ 
• 870997-85-6 3-amino-5-bromo-pyridine-2-carboxylic acid 

Relevant articles and documents

PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS

The present disclosure is directed to compounds of Formula (I): which modulate PD-1/PD-L1 protein/protein interaction, compositions, and methods of treating various diseases, including infectious diseases and cancer.

CD73 INHIBITORS

Disclosed are compounds that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions, and compositions containing the compounds.

Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity

There is an urgent need for strategies to combat dengue and other emerging viral infections. We reported that cyclin G-associated kinase (GAK), a cellular regulator of the clathrin-associated host adaptor proteins AP-1 and AP-2, regulates intracellular trafficking of multiple unrelated RNA viruses during early and late stages of the viral lifecycle. We also reported the discovery of potent, selective GAK inhibitors based on an isothiazolo[4,3-b]pyridine scaffold, albeit with moderate antiviral activity. Here, we describe our efforts leading to the discovery of novel isothiazolo[4,3-b]pyridines that maintain high GAK affinity and selectivity. These compounds demonstrate improved in vitro activity against dengue virus, including in human primary dendritic cells, and efficacy against the unrelated Ebola and chikungunya viruses. Moreover, inhibition of GAK activity was validated as an important mechanism of antiviral action of these compounds. These findings demonstrate the potential utility of a GAK-targeted broad-spectrum approach for combating currently untreatable emerging viral infections.